Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C]JNT-517 in Healthy Males
NCT07573449Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of repinatrabit in phenylketonuria (PKU), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Total Radioactivity Recovery (fet1-t2) in Urine and Feces, Relative Amounts Of Radioactivity Excreted in Urine and Feces and 10 more. Started Jan 2024; status: completed.
02
Drugs
repinatrabit
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT07573449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07573449.